Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2016 Feb 25

PMID 26909818

Citations 1

Authors

Rochelle Sweis

Jose Biller

Affiliations

Soon will be listed here.

Abstract

Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.

Citing Articles

Reporting quality evaluation of the stroke clinical practice guidelines: a systematic review.

Lu S, Luo X, Ni X, Li H, Meng M, Cai Y Syst Rev. 2021; 10(1):262.

PMID: 34593016 PMC: 8485553. DOI: 10.1186/s13643-021-01805-3.

References

Morgenstern L, Hemphill 3rd J, Anderson C, Becker K, Broderick J, Connolly Jr E . Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41(9):2108-29. PMC: 4462131. DOI: 10.1161/STR.0b013e3181ec611b. View

Del Zoppo G, Eliasziw M . New options in anticoagulation for atrial fibrillation. N Engl J Med. 2011; 365(10):952-3. DOI: 10.1056/NEJMe1107516. View

Connolly S, Wallentin L, Ezekowitz M, Eikelboom J, Oldgren J, Reilly P . The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013; 128(3):237-43. DOI: 10.1161/CIRCULATIONAHA.112.001139. View

Banerjee A, Lane D, Torp-Pedersen C, Lip G . Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2011; 107(3):584-9. DOI: 10.1160/TH11-11-0784. View

Olesen J, Lip G, Lindhardsen J, Lane D, Ahlehoff O, Hansen M . Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106(4):739-49. DOI: 10.1160/TH11-05-0364. View

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21):e1-76. DOI: 10.1016/j.jacc.2014.03.022. View

Gladstone D, Geerts W, Douketis J, Ivers N, Healey J, Leblanc K . How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the.... Ann Intern Med. 2015; 163(5):382-5. DOI: 10.7326/M15-0143. View

Huang D, Anguo L, Yue W, Yin L, Tse H, Siu C . Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1. Pacing Clin Electrophysiol. 2014; 37(11):1442-7. DOI: 10.1111/pace.12445. View

Chatterjee S, Sardar P, Giri J, Ghosh J, Mukherjee D . Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc. 2014; 89(7):896-907. DOI: 10.1016/j.mayocp.2014.01.030. View

10.

Horlocker T . Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy. Br J Anaesth. 2011; 107 Suppl 1:i96-106. DOI: 10.1093/bja/aer381. View

11.

Pollack Jr C, Reilly P, Eikelboom J, Glund S, Verhamme P, Bernstein R . Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015; 373(6):511-20. DOI: 10.1056/NEJMoa1502000. View

12.

Lane D, Lip G . Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012; 126(7):860-5. DOI: 10.1161/CIRCULATIONAHA.111.060061. View

13.

Verheugt F, Granger C . Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015; 386(9990):303-10. DOI: 10.1016/S0140-6736(15)60245-8. View

14.

Dunn A, Turpie A . Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003; 163(8):901-8. DOI: 10.1001/archinte.163.8.901. View

15.

Holmes Jr D, Doshi S, Kar S, Price M, Sanchez J, Sievert H . Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015; 65(24):2614-2623. DOI: 10.1016/j.jacc.2015.04.025. View

16.

Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C . Laboratory assessment of rivaroxaban: a review. Thromb J. 2013; 11(1):11. PMC: 3726412. DOI: 10.1186/1477-9560-11-11. View

17.

Lip G, Skjoth F, Rasmussen L, Larsen T . Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015; 65(14):1385-94. DOI: 10.1016/j.jacc.2015.01.044. View

18.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

19.

Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M . Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50(7):743-53. DOI: 10.1177/0091270009351883. View

20.

Olesen J, Torp-Pedersen C, Hansen M, Lip G . The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107(6):1172-9. DOI: 10.1160/TH12-03-0175. View